HONG KONG – Chinese biopharma company Huya Bioscience International LLC extended its global partnership and commercialization business model to South Korea, looking to replicate the success it has had taking promising compounds from one country – mostly China – and developing them elsewhere. Read More
HONG KONG – Australian researchers led by the University of New South Wales (UNSW) have discovered the mechanism whereby synaptic connections between brain cells are destroyed in the early stages of Alzheimer's disease (AD), a key finding that clears the way for new research on urgently needed treatments for the currently incurable degenerative brain disease. Read More
NEW DELHI – Indian generics drugmaker Cipla Ltd. said it will explore all legal options available after an Indian court's recent ruling that the firm infringed the patent rights of Swiss drug major Roche AG regarding lung cancer drug erlotinib. Read More
SHANGHAI – In what could be called a surprising about-face, Eisai Co. Ltd. has bought itself a small piece of China's generic market with the acquisition of Liaoning Tianyi Biological Pharmaceutical Co. Ltd., for $78.2 million. Eisai's execs said they are hoping to take advantage of a segment they believe will see robust growth in the coming years in China: high-quality generic drugs. Read More
SHANGHAI – Getting a drug to patients in China's huge, fractured market is no easy task. But it is a challenge China's state-owned firm, Sinopharm Group, happens to have well under control: It is China's biggest drug distributor, and, not surprisingly, it is the first firm in China's health care sector to make the Fortune 500 list. Last year, Sinopharm's revenues topped $30 billion. Read More
HONG KONG – Three-year old Chinese novel monoclonal antibody (MAb) developer Akeso Biopharma Inc. has signed a $200 million deal with MSD China, out-licensing its first compound. The deal comes on the heels of closing a $20 million series A financing funded by local investors. Read More